Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2010 - 2025)

Arbutus Biopharma (ABUS) has reported Non-Current Deffered Revenue for 12 consecutive years, with $2.9 million the latest figure, recorded in Q1 2025.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $2.9 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.9 million (changed N/A YoY) and the FY2024 annual result came in at $2.9 million, changed N/A from the prior year.
• Non-Current Deffered Revenue was little changed at $2.9 million in Q1 2025 per ABUS's latest filing, from $2.9 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ABUS reached as high as $15.6 million in Q1 2022 and fell as low as $2.9 million in Q4 2024.
• A 4-year average of $7.4 million and a median of $6.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The largest YoY upside for Non-Current Deffered Revenue was 78.85% in 2023 against a maximum downside of 78.85% in 2023.
• Year by year, Non-Current Deffered Revenue stood at $6.0 million in 2022, then tumbled by 45.06% to $3.3 million in 2023, then slipped by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.9 million, $2.9 million, and $3.3 million for Q1 2025, Q4 2024, and Q1 2023 respectively.